Live
- All you need to know about PAN 2.0
- Akasa Air redefines travel experience with industry-first offerings
- MP: Residents stage protests against liquor shop in Indore
- Telugu Actor Shri Tej Booked for Alleged Cheating and False Promise of Marriage in Live-in Relationship
- Toyota Kirloskar Motor Celebrates 1 Lakh Urban Cruiser Hyryder on Indian Road
- MLS: New York City FC part ways with head coach Nick Cushing
- Delhi CM says Centre cutting AAP voters’ names from rolls, BJP hits back
- Hyderabad Metro Rail Phase-II Works to Begin in Old City in January 2025
- Odisha: 668 persons killed in human-elephant conflicts in last three years
- DEFENDER JOURNEYS: TO EMBARK ON ITS THIRD EDITION FROM NOVEMBER 2024
SII's Covovax gets WHO nod
SII’s Covovax gets WHO nod
Highlights
The World Health Organisation (WHO) on Friday issued an emergency use listing to Covovax, Serum Institute of India's version of Novavax Inc's Covid-19 vaccine.
New Delhi: The World Health Organisation (WHO) on Friday issued an emergency use listing to Covovax, Serum Institute of India's version of Novavax Inc's Covid-19 vaccine.
The WHO in a press release said, "Today, the World Health Organization issued an emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus.
The vaccine, named Covovax, is produced by the Serum Institute of India under licence from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries."
Next Story
ADVERTISEMENT
